Merck, Stelis opens first process scale-up lab in Bengaluru, India

Merck, Stelis opens first process scale-up lab in Bengaluru, India

11:19 AM, 15th May 2017
Merck, Stelis opens first process scale-up lab in Bengaluru, India
Offers seamless, robust transfer of optimized processes from smallscale R&D lab to large-scale commercial manufacturing.

DARMSTADT, GERMANY: Merck Group in collaboration with Stelis Biopharma Pvt Ltd has opened its first joint process scale-up lab in Bengaluru, India. This lab provides end-to-end solutions from process development to scale-up manufacturing for pre-clinical, clinical and commercial supply.

This lab is located at the Stelis Biopharma R&D facility in the Jigani industrial estate. 

The collaboration reinforces Merck’s position as the premier supplier of process development and clinical state manufacturing solutions, materials and services needed for biologics production.

The lab is a centre of excellence for process scale-up and manufacturing services. The collaboration brings together Stelis’ end-to-end capabilities in high-yield bioprocess development from cell line to commercial manufacturing scale and Merck’s industry-leading technological expertise in bioprocessing.

The process scale-up lab and a soon-to-be-completed cGMP manufacturing facility will house Merck’s portfolio of Mobius bioprocessing equipment and single-use manufacturing components. Merck will provide process know-how and application knowledge to help establish the single-use platform technologies at Stelis as part of the collaboration.

“Both Merck and Stelis bring technological expertise and an extensive bioprocess development and manufacturing portfolio that will help customers accelerate development of biopharmaceuticals for clinical trials and manufacturing with greater reliability and cost effectiveness,” said Udit Batra, member of the Merck executive board and CEO, life science.

“In the biopharma space, where the process is the product, our process scale-up lab fulfils a critical need by offering clients a reliable process bridge between R&D and commercial scales. The collaboration with Merck completes the value proposition for CDMO customers by providing an end-to-end solution from process development and scale-up through to manufacturing for pre-clinical, clinical and commercial supply,” said Joe Thomas, CEO of Stelis Biopharma.

© Worldofchemicals News 



Your Comments (Up to 2000 characters)
Please respect our community and the integrity of its participants. WOC reserves the right to moderate and approve your comment.

Related News

Ashland completes final separation of Valvoline

COVINGTON, US: Ashland Global Holdings Inc (ASH) said that it has completed the previously announced distribution of 170,000,000 shares of common stoc ...

Read more
AkzoNobel, Atul JV to start MCA production in India in 2019

AMSTERDAM, NETHERLANDS/ VALSAD, INDIA: AkzoNobel NV and Atul Ltd have formally agreed on the joint venture partnership announced last year for the pro ...

Read more
Designer uses Covestro materials to create piece of furniture

LEVERKUSEN, GERMANY: Furniture designer Thomas Schnur has created a one of a kind piece, named “The Factory of Ideas”, using a range of in ...

Read more
ANL, NREL receives fund to support Gevo’s isobutanol- gasoline blending

ENGLEWOOD, US: Gevo Inc (GEVO) said that it was selected to collaborate with researchers at the US Department of Energy (DOE) as part of DOE’s S ...

Read more
Total inaugurates revamped petrochemical complex in Carling, France

PARIS, FRANCE: Total SA has inaugurated its revamped Carling – Saint-Avold petrochemical complex in eastern France, following 3 years of renovat ...

Read more
Sika relocates concrete admixture plant in Kazakhstan

BAAR, SWITZERLAND: Sika AG has relocated its concrete admixture and mortar production in Almaty, Kazakhstan, to a larger site in the city. Aside from ...

Read more uses cookies to ensure that we give you the best experience on our website. By using this site, you agree to our Privacy Policy and our Terms of Use. X